Amplo is treating diseases of the neuro-muscular junction (including congenital myasthenia syndrome, ALS, and muscular dystrophies) by one-time Dok7-gene therapy
Location: United States, Florida, Pompano Beach
Investors 2
| Date | Name | Website |
| - | SeedFolio | seedfolio.... |
| - | Biobrit | biobrit.co... |
Mentions in press and media 3
| Date | Title | Description |
| 17.10.2024 | Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress | SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and ... |
| 29.05.2023 | Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency | SAN DIEGO, May 29, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders announced the award of a Fast Track Phase I/II ... |
| 29.05.2023 | Amplo Biotechnology Receives Fast Track Phase I/II STTR Grant from NIH-NIAMS | Amplo Biotechnology, a San Diego, CA-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders, announced the award of a Fast Track Phase I/II STTR grant from the NIH-NIAMS. This ... |